Ofatumumab
- Generic Name
- Ofatumumab
- Brand Names
- Arzerra, Kesimpta
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 679818-59-8
- Unique Ingredient Identifier
- M95KG522R0
- Background
Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and...
- Indication
Ofatumumab is indicated, in combination with chlorambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) for whom fludarabine-based therapy is considered inappropriate.
...
- Associated Conditions
- Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL) - Refractory, Clinically Isolated Syndrome (CIS), Relapsing Multiple Sclerosis (RMS), Relapsing Remitting Multiple Sclerosis (RRMS), Active Secondary Progressive Multiple Sclerosis (SPMS), Progressive Chronic Lymphocytic Leukaemia (CLL), Recurrent Chronic Lymphocytic Leukaemia (CLL)
- Associated Therapies
- -
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2014-06-04
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 223
- Registration Number
- NCT00349349
HuMax-CD20 in Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00093314
- Locations
- 🇺🇸
University of Iowa, Hospitals and Clinics, Iowa City, Iowa, United States
Study of HuMax-CD20, a New Drug to Treat Early Stage Non-Hodgkin´s Follicular Lymphoma
- Conditions
- First Posted Date
- 2004-09-27
- Last Posted Date
- 2015-04-21
- Lead Sponsor
- GlaxoSmithKline
- Registration Number
- NCT00092274
- Locations
- 🇺🇸
University of Iowa Hospitals and Clinics, Iowa City, Iowa, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.